Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J.

Clin Cancer Res. 2018 Apr 23. doi: 10.1158/1078-0432.CCR-18-0201. [Epub ahead of print]

PMID:
29685879
2.

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, Wesseling J.

Breast. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001. Epub 2016 Sep 23. Review.

3.

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation.

Ruben JM, Visser LL, Heinhuis KM, O'Toole T, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

PLoS One. 2015 Aug 7;10(8):e0135219. doi: 10.1371/journal.pone.0135219. eCollection 2015.

4.

T cell memory. Skin-resident memory CD8⁺ T cells trigger a state of tissue-wide pathogen alert.

Ariotti S, Hogenbirk MA, Dijkgraaf FE, Visser LL, Hoekstra ME, Song JY, Jacobs H, Haanen JB, Schumacher TN.

Science. 2014 Oct 3;346(6205):101-5. doi: 10.1126/science.1254803. Epub 2014 Aug 28.

5.

Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.

Ruben JM, Visser LL, Bontkes HJ, Westers TM, Ossenkoppele GJ, de Gruijl TD, van de Loosdrecht AA.

Immunotherapy. 2013 Aug;5(8):859-68. doi: 10.2217/imt.13.76. Review.

PMID:
23902555

Supplemental Content

Loading ...
Support Center